

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AstraZeneca (durvalumab, olaparib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Cancer Black Care	Wales
Cancer Equality	British National Formulary
Cancer 52	Care Quality Commission
Endometriosis Foundation	Department of Health - Northern Ireland
Eve Appeal	Healthcare Improvement Scotland
Go Girls	Medicines and Healthcare products
Helen Rollason Cancer Charity	Regulatory Agency
Independent Cancer Patients Voice	 National Association of Primary Care
Macmillan Cancer Support	 National Pharmacy Association
Maggie's Centres	NHS Confederation
Marie Curie	Scottish Medicines Consortium
 Peaches Womb Cancer Trust 	Welsh Government
 South Asian Health Foundation 	Welsh Health Specialised Services
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	
Wellbeing of Women	Possible comparator companies
Womb Cancer Support UK	Accord (carboplatin, paclitaxel, cisplatin,
Women's Health Concern	doxorubicin)
	Alliance Healthcare (cisplatin,
Healthcare professional groups	cyclophosphamide, paclitaxel)
Association of Anaesthetists	Bausch & Lomb (megestrol acetate) Payton Haalthaans (system bank and and acetate)
Association of Cancer Physicians	Baxter Healthcare (cyclophosphamide) Bristal Myore Sayibb Pharmagayitigala
Association of Surgeons of Great	Bristol Myers Squibb Pharmaceuticals (paglitayel)
Britain and Ireland	(paclitaxel)
British Association of Surgical	Consilient Health (carboplatin) Freeding Kabi (carboplatin, paclitavel)
Oncology	Fresenius Kabi (carboplatin, paclitaxel)
British Geriatrics Society	Hospira UK (carboplatin, paclitaxel) Modes CmbH (deverybigin)
British Gynaecological Cancer Society	Medac GmbH (doxorubicin) Dizar (aarbanlatin na alitaval aianlatin
British Institute of Radiology	Pfizer (carboplatin, paclitaxel, cisplatin,

Final stakeholder list for the evaluation of durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 Issue date: July 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Clinical Cytology British Society for Colposcopy and Cervical Pathology Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians and Gynaecologists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	doxorubicin, medroxyprogesterone acetate) Sandoz (cisplatin, cyclophosphamide) Seacross Pharmaceuticals (paclitaxel, doxorubicin) Teva UK (carboplatin, cisplatin, paclitaxel) Relevant research groups Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Final stakeholder list for the evaluation of durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 Issue date: July 2024



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.